Company Number: 14123869

Analysis Date: 2025-07-29 12:19 UTC

1. Credit Opinion: DECLINE
   Birchester Medicare Services Limited is a newly incorporated entity (May 2022) with no substantive trading history or financial performance data beyond dormant accounts as of 31 October 2022. The company shows minimal net assets (£100) and no evidence of operational cash flows or profitability. Without material financial data or trading history, the company lacks demonstrated capacity to service debt or meet commercial obligations. The absence of audited or detailed financials further limits credit visibility. Given this, extending credit at this stage would carry high risk.

2. Financial Strength:
   The company’s balance sheet as of the last accounts filing (year ending October 2022) is essentially nominal, showing only issued share capital of £100 and net assets of £100. There are no fixed or current assets, no liabilities, no working capital, and no retained earnings. This indicates the company had not commenced trading or accumulated resources to support business operations. The financial position is therefore very weak and provides no buffer against business or economic shocks.

3. Cash Flow Assessment:
   No financial statements beyond dormant accounts are available, so there is no information on cash flow generation, liquidity, or working capital management. The company’s ability to generate cash from operations or maintain liquidity is unproven. The absence of current assets or any reported income suggests the company is not yet operational or generating cash inflows. This presents a liquidity risk if credit is extended.

4. Monitoring Points:

• Obtain updated financial statements showing trading performance, revenues, profit margins, and cash flows once available.
• Monitor net current assets and working capital levels to assess operational liquidity.
• Review director reports or management commentary for strategic plans and risk mitigation measures.
• Track payment history on any existing trade or financing arrangements.
• Assess any equity injections or capital increases that may strengthen the balance sheet.